EVMed Group Biotechnology

Lingqiang ZHU, Ph.D.

Professor of Huazhong University of Science and Technology Neurology Consultant

Zhigang WANG, M.D.

Director of Shanghai Meilifang Hospital Medical Aesthetics Consultant

Junli LIU, Ph.D.

Professor of Shanghai Jiao Tong University

Pharmacy Consultant

Yi ZHENG, M.D.

Shenzhen Guangming Hospital Director Laboratory Consultant

ABOUT US

EVMed Group has a highly experienced team with nearly a decade of expertise in exosome product development, supported by strong pharmaceutical R&D and manufacturing capabilities. The company has established long-term strategic partnerships with leading global pharmaceutical and biotech companies. Driven by a commitment to technological innovation, EVmed continues to increase its investment in exosome-related research and development. The company also collaborates with top scientific research institutes to build innovation platforms, ensuring the long-term growth and success of its business.

Bo GAO, Ph.D.

Jiangxi Agricultural University,

off-campus graduate tutor

Shaoxing Special Evaluation Expert

From 2006 to 2015, he was General Manager at Shanghai Jikai Gene Technology, overseeing production of recombinant virus vectors (lentivirus, adenovirus, AAV). Since 2016, he has been the Founder & CEO of Shanghai Umibio Biotechnology, focusing on exosome product development and process optimization. He led multiple research projects, including glioma mechanism studies, tumor drug screening, and RNA-based cancer therapies, with 30 patents and 13 publications, including 7 SCI articles.

Yun WANG, Ph.D.

Fudan University Senior PI,Researcher, Doctoral Supervisor

Graduating from Fudan University (1987), he earned a PhD in neurophysiology from Glasgow University (1995) with a Wellcome Trust Scholarship. He worked as a postdoc at University College London before joining Eli Lilly's UK R&D Center in 2000. He has led several major research projects, including the Wellcome Trust Fund and BBSRC projects in the UK, and has overseen key research initiatives funded by China's Natural Science Foundation and Ministry of Education.

Getao SHI, Ph.D.

R & D Director

Ph.D., Ecole Normale Supérieure de Paris, FranceFormer French Curie laboratory, postdoctoral researcherFrom 2006 to 2010, he was responsible for the research on the mechanism of vesicle transport in the Curie laboratory in France;From 2010 to 2016, participated in the research and development of Shiga toxin-directed anticancer drugs in the Curie laboratory in France.

Hongwei WANG, Ph.D.

Nanjing University School of MedicineProfessor,

Doctoral Supervisor

The Executive Director of the Jiangsu Biotechnology Society and a Jiangsu "Qinglan Project" academic leader. His research focuses on epigenetics in chronic inflammation and muscle degradation, with leadership in four National Science Foundation projects and several funded by the Ministry of Science and Technology.

Xiang ZHOU, Ph.D.

Researcher at Fudan University

In 2016, he became the PI at Fudan University Cancer Hospital/Tumor Research Institute and is now Assistant Director of the Cancer Research Institute. He received the US-China Anti-Cancer Association Academic Award and funding from the National Natural Science Foundation of China. His research focuses on tumorigenesis, metastasis, TP53 gene mutations, non-coding RNA, and ribosome stress inhibition in cancer. He has published over 30 papers in top journals like Mol Cell and Nat Commun.

Yongxian LAI, M.D.

Shanghai Dermatology Hospital Doctor of Medicine,

Chief Physician, Senior Dermatologist

A Visiting Scholar at the University of Zurich's Department of Dermatology and Cranio-Maxillofacial Surgery, with over 15 years in plastic surgery. He has led numerous research projects and is a leading expert in skin regenerative medicine, blending innovation, and patient-centered care.